TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32682429

Group type: EXPERIMENTAL
Intervention: Multimodal intervention including teaching materials on aseptic procedures, flexibly mountable alcoholic hand rub dispensers, and quarterly feedback on HH compliance.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multimodal intervention.
Number of subjects: 20
Study: 35641409

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and dexamethasone (Isa-Pd)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone (Pd)
Number of subjects: 36
Study: 34128526

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (normal saline) injections
Number of subjects: 40
Study: 32144053

Group type: EXPERIMENTAL
Intervention: Cell salvage
Number of subjects: 716

Group type: COMPARATOR
Intervention: Control
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Allogeneic transfusion
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Processed cell salvage blood
Number of subjects: 716
Study: 34756640

Group type: EXPERIMENTAL
Intervention: Occlusal Splints (OS)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High‐Intensity Laser Therapy (HILT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study: 32349662

Group type: EXPERIMENTAL
Intervention: Triptan insufficient responders (TIRs)
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Triptan responders (TRs)
Number of subjects: 1413
Study: 35404684

Group type: EXPERIMENTAL
Intervention: Fuzuloparib (150 mg, twice daily)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 33731311

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard oncologic care (SOC)
Number of subjects: 23
Study: 35266296

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 8246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study: 33656232

Group type: EXPERIMENTAL
Intervention: WeChat-assisted health education
Number of subjects: 70

Group type: COMPARATOR
Intervention: Leaflet group (control)
Number of subjects: 70
Study: 37036305

Group type: EXPERIMENTAL
Intervention: Pediatric Opioid Analgesia Self-Instruction System (PedOASIS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual PHO training (control)
Number of subjects: 64
Study: 33142249

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/ml
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/ml
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 μg/ml
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dexmedetomidine 0 μg/ml
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.3 μg/ml
Number of subjects: 150
Study: 32592381

Group type: EXPERIMENTAL
Intervention: 20Gy/5fr
Number of subjects: 22

Group type: COMPARATOR
Intervention: 27Gy/3fr
Number of subjects: 22
Study: 34533758

Group type: EXPERIMENTAL
Intervention: BMI 25.0-29.9 kg/m2
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: BMI 30.0-34.9 kg/m2
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: BMI 35.0-39.9 kg/m2
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: BMI ≥ 40.0 kg/m2
Number of subjects: 4956

Group type: COMPARATOR
Intervention: Normal BMI (18.5-24.9 kg/m2)
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30.0 kg/m2)
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: Obesity (BMI 30.0-34.9 kg/m2)
Number of subjects: 4956

Group type: EXPERIMENTAL
Intervention: Obesity (BMI 35.0-39.9 kg/m2)
Number of subjects: 4956
Study: 33751402

Group type: EXPERIMENTAL
Intervention: LPS administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 35320921

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no ASCT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) in advanced stage subgroup
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no ASCT) in advanced stage subgroup
Number of subjects: 174
Study: 32217780

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 202
Study: 34225347

Group type: EXPERIMENTAL
Intervention: REBOA-RATE assessment
Number of subjects: 42
Study: 33031148

Group type: EXPERIMENTAL
Intervention: Intervention associated mortality
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group mortality
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clinically important treatment benefit or harm
Number of subjects: 101
Study: 35907504

Group type: EXPERIMENTAL
Intervention: Low-dose Prasugrel or Clopidogrel
Number of subjects: 1364
Study: 34668436

Group type: EXPERIMENTAL
Intervention: 75 g of ketone ester (KE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 300 mg/kg body mass bicarbonate (BIC)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: KE + BIC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control drink with 60 g of carbohydrates/h
Number of subjects: 14
Study: 35246135

Group type: EXPERIMENTAL
Intervention: LOCI intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-LOCI conditions
Number of subjects: 47
Study: 33824227

Group type: EXPERIMENTAL
Intervention: Genetically predicted IBD
Number of subjects: 75000
Study: 35317870

Group type: EXPERIMENTAL
Intervention: Probiotic gargles for 14 days post-surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gargles for 14 days post-surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Probiotic and placebo groups
Number of subjects: 30
Study: 32852139

Group type: EXPERIMENTAL
Intervention: FKB327 (F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference Product (RP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F-F-F (no switch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F-RP-F (single switch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RP-F-F (single switch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RP-RP-F (double switch)
Number of subjects: 0
Study: 36102630

Group type: EXPERIMENTAL
Intervention: 2-week postoperative oral antibiotics
Number of subjects: 38

Group type: COMPARATOR
Intervention: 12-week postoperative oral antibiotics
Number of subjects: 38
Study: 33714226

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (exenatide and pioglitazone or basal-bolus insulin)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control in patients with pDPN
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control in patients without pDPN
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (18 participants at baseline only)
Number of subjects: 41
Study: 615924469

Group type: COMPARATOR
Intervention: No micro-scotomas
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 39% micro-scotomas at the fovea
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 39% micro-scotomas at 5 deg eccentricity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 39% micro-scotomas at 10 deg eccentricity
Number of subjects: 5
Study: 35037037

Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 850
Study: 34043778

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion at 70 mmHg (NMP-70)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Static cold storage
Number of subjects: 10
Study: 35538000

Group type: COMPARATOR
Intervention: Standard oral and written information
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Standard oral and written information plus additional educational video
Number of subjects: 69
Study: 32976051

Group type: EXPERIMENTAL
Intervention: Olive pâté (4 tablets/day corresponding to 30 mg/day of hydroxytyrosol)
Number of subjects: 19
Study: 35144973

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 224

Group type: COMPARATOR
Intervention: MRCP
Number of subjects: 224
Study: 34346827

Group type: EXPERIMENTAL
Intervention: MW33 (4 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, 60 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MW33 (10-60 mg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MW33
Number of subjects: 42
Study: 35648692

Group type: EXPERIMENTAL
Intervention: Multidimensional nursing intervention for pain
Number of subjects: 132
Study: 33243172

Group type: EXPERIMENTAL
Intervention: mHealth clinical decision-making support system (mCDMSS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no mCDMSS)
Number of subjects: 16
Study: 36644732

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 17

Group type: COMPARATOR
Intervention: Aspiration alone
Number of subjects: 17
Study: 33483869

Group type: EXPERIMENTAL
Intervention: Premixed bioceramic (BC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 76
Study: 32967391

Group type: EXPERIMENTAL
Intervention: PIFB-Pecs II group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pecs II group
Number of subjects: 60
Study: 36240577

Group type: EXPERIMENTAL
Intervention: Disinhibited eating qualities (including LOC, overeating, eating more than planned, mindless eating, concerns about wasting food, encouragement to eat more)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Loss of control (LOC) eating
Number of subjects: 42
Study: 35267178

Group type: EXPERIMENTAL
Intervention: Home visits from birth to age 3 years
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Center-based early childhood education from ages 1 to 3 years
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Infant Health and Development Program (IHDP)
Number of subjects: 1090
Study: 32958697

Group type: EXPERIMENTAL
Intervention: Elevated hs-CRP levels and multiple acute infarctions (MAIs)
Number of subjects: 807

Group type: COMPARATOR
Intervention: Non-elevated hs-CRP levels and no acute infarction (NAI)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Composite events
Number of subjects: 807
Study: 32232698

Group type: EXPERIMENTAL
Intervention: Tailored dose-dense chemotherapy (four cycles of epirubicin and cyclophosphamide every 2 weeks followed by four cycles of docetaxel every 2 weeks)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Standard chemotherapy (three cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by three cycles of docetaxel every 3 weeks)
Number of subjects: 760
Study: 36194912

Group type: EXPERIMENTAL
Intervention: Suspended social media use for one week
Number of subjects: 93

Group type: COMPARATOR
Intervention: Used social media as normal
Number of subjects: 93
Study: 33428901

Group type: EXPERIMENTAL
Intervention: Extracorporeal life support (ECLS) in addition to early revascularization with percutaneous coronary intervention or coronary artery bypass grafting and optimal medical treatment
Number of subjects: 420

Group type: COMPARATOR
Intervention: No ECLS
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: ECLS
Number of subjects: 420
Study: 36173031

Group type: EXPERIMENTAL
Intervention: Synbiotics capsule plus anti-inflammatory-antioxidant rich diet
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo capsule plus dietary recommendations
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Synbiotics and dietary intervention
Number of subjects: 69
Study: 34184929

Group type: EXPERIMENTAL
Intervention: Testosterone levels during androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant PSA values
Number of subjects: 0
Study: 32065299

Group type: EXPERIMENTAL
Intervention: Low-temperature plasma radiofrequency ablation (coblation)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 95
Study: 35373693

Group type: EXPERIMENTAL
Intervention: Needling/microneedling in conjunction with NB‐UVB phototherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: NB‐UVB monotherapy
Number of subjects: 20
Study: 34129067

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 329
Study: 34959749

Group type: EXPERIMENTAL
Intervention: Flavoured water (FW)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Plain water (W)
Number of subjects: 18
Study: 33785196

Group type: EXPERIMENTAL
Intervention: Direct access to physiotherapy services
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Traditional GP-referral to NHS physiotherapy
Number of subjects: 10000
Study: 33334450

Group type: EXPERIMENTAL
Intervention: High-dose Dobutamine (DBT) (40 to 50 μg/kg/min for 10 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-dose Isoproterenol (IPN) (20 to 30 μg/min for 10 min)
Number of subjects: 50
Study: 35560162

Group type: EXPERIMENTAL
Intervention: Screen-detected breast cancer screening
Number of subjects: 79354

Group type: COMPARATOR
Intervention: Clinically detected breast cancer screening
Number of subjects: 79354

Group type: EXPERIMENTAL
Intervention: Screening program (both modalities)
Number of subjects: 79354
Study: 33592825

Group type: EXPERIMENTAL
Intervention: Modified selective spinal massage method combined with basic rehabilitation treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Basic rehabilitation treatment
Number of subjects: 182
Study: 35689890

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2000 mg/d)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2000 mg/d) in male participants
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2000 mg/d) in female participants
Number of subjects: 58
Study: 33075197

Group type: EXPERIMENTAL
Intervention: 10% sinecatechins ointment applied three times daily for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo ointment applied three times daily for 16 weeks
Number of subjects: 26
Study: 32729407

Group type: EXPERIMENTAL
Intervention: Standardized vagus nerve massage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standardized soft shoulder massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 60
Study: 36042484

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 298

Group type: COMPARATOR
Intervention: Sevoflurane inhalation
Number of subjects: 298
Study: 34417989

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32250336

Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training at 60‐80% of heart rate reserve
Number of subjects: 22

Group type: COMPARATOR
Intervention: Outdoor-overground walking below 40% of heart rate reserve
Number of subjects: 22
Study: 36432526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33887445

Group type: EXPERIMENTAL
Intervention: Painful isometric shoulder exercises (external rotation; 20% above pain threshold)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nonpainful isometric shoulder exercises (external rotation; 20% below pain threshold)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 35
Study: 32899037

Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 or 15 mg twice daily (BID)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg BID
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Mirogabalin (flexible dosing)
Number of subjects: 239
Study: 34957728

Group type: EXPERIMENTAL
Intervention: Prognostic covariate adjustment using historical data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic models that explain a clinically realistic percentage of the outcome variance
Number of subjects: 0
Study: 33070988

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers (fecal calprotectin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological healing
Number of subjects: 0
Study: 35078545

Group type: EXPERIMENTAL
Intervention: VR Blue (30-min virtual underwater/sea environment)
Number of subjects: 20
Study: 33856487

Group type: EXPERIMENTAL
Intervention: Traditional advertising channels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Instagram advertising
Number of subjects: 160
Study: 36472718

Group type: EXPERIMENTAL
Intervention: Square-wave insulin bolus (SQ)
Number of subjects: 58
Study: 34140179

Group type: EXPERIMENTAL
Intervention: Personalized SMS text-message-based weight loss intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 80
Study: 36448347

Group type: EXPERIMENTAL
Intervention: Traditional prenatal health mission combined with desktop VR health education system mode
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional health education mode
Number of subjects: 200
Study: 33445223

Group type: EXPERIMENTAL
Intervention: DIDP scale
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: ADDQoL-19 scale
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Diabetes QoL-Q scale
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: DSQOLS scale
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: DCP scale
Number of subjects: 1578
Study: 32007123

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) applied post-surgery, maintaining negative pressure at -125 mmHg for five days.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard surgical dressings (SSD) as a comparison to NPWT.
Number of subjects: 19
Study: 32755035

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 43

Group type: COMPARATOR
Intervention: No belimumab (RC group)
Number of subjects: 43
Study: 32200266

Group type: EXPERIMENTAL
Intervention: Immediate oral intake of low-fat solid food (15 g/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard food with gradually increasing amounts of dietary fat
Number of subjects: 26
Study: 34716211

Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 25

Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 25
Study: 33836711

Group type: EXPERIMENTAL
Intervention: Brainwork Intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 35026964

Group type: EXPERIMENTAL
Intervention: Low-intensity ultrasound (LIUS)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Sham ultrasound treatment (Control)
Number of subjects: 498
Study: 33941624

Group type: EXPERIMENTAL
Intervention: Generic questionnaire with 11 health items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic questionnaire with 44 health items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic questionnaire with 56 health items
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provider records (gold standard)
Number of subjects: 0
Study: 33338325

Group type: EXPERIMENTAL
Intervention: Multimodal occupational therapy (including patient education, hand exercises, orthoses, and assistive devices)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual treatment (OA information)
Number of subjects: 180
Study: 35045228

Group type: EXPERIMENTAL
Intervention: SER-109 (four capsules daily for 3 days)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (four capsules daily for 3 days)
Number of subjects: 182
Study: 33051650

Group type: EXPERIMENTAL
Intervention: Amphotericin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphotericin with flucytosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphotericin with fluconazole
Number of subjects: 0
Study: 32524497

Group type: EXPERIMENTAL
Intervention: Kidneys from donors with PUJ dysfunction
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (kidneys from donors without PUJ dysfunction)
Number of subjects: 198
Study: 35241042

Group type: EXPERIMENTAL
Intervention: Peer-delivered HIV self-testing (HIVST) intervention
Number of subjects: 30
Study: 34256413

Group type: EXPERIMENTAL
Intervention: Physiological ICSI (PICSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ICSI
Number of subjects: 0
Study: 33010038

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34264000

Group type: EXPERIMENTAL
Intervention: Chronic Care Model-based intervention (StrokeCARE protocol) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine patient care (control group)
Number of subjects: 0
Study: 33397352

Group type: EXPERIMENTAL
Intervention: Lower-limb complications (PAD or neuropathy)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy
Number of subjects: 11140

Group type: COMPARATOR
Intervention: No lower-limb complications
Number of subjects: 11140
Study: 32700926

Group type: EXPERIMENTAL
Intervention: Countering emotional behaviors module from the unified protocol
Number of subjects: 8
Study: 35195914

Group type: EXPERIMENTAL
Intervention: Think Bright training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (regular training regimen)
Number of subjects: 68
Study: 33955183

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35276079

Group type: EXPERIMENTAL
Intervention: Amisulpride plus olanzapine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Amisulpride plus placebo
Number of subjects: 328

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 328
Study: 32470147

Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 0
Study: 616774451

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 90
Study: 32052014

Group type: EXPERIMENTAL
Intervention: DAAs
Number of subjects: 1078

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 1078

Group type: COMPARATOR
Intervention: IFN nonresponders
Number of subjects: 1078
Study: 33150235

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) awareness and practice education
Number of subjects: 354